Synovial Sarcoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Synovial Sarcoma (SS) is a soft tissue sarcoma that mimics a benign neoplasm due to its slow growth and distal predisposition. A slow-growing mass, compression symptoms, or irritation to nearby structures are all common symptoms of SS. These cancers are well-known for their proclivity for being misdiagnosed. They've been said to look like arthritis, synovitis, bursitis, hemangiomas, and hematomas, especially when small calcifications accompany them. SS affects specific areas, with 60 percent to 70 percent of cases affecting the lower extremity, and is frequently associated with bursae, tendon sheaths, and joint capsules. Monophasic and biphasic SS are the two major subtypes of SS histologically. Monophasic tumors, found in all three of our patients, are made up of spindled cells and have a better prognosis. They usually present as smaller masses with no metastases.

The incidence of Synovial Sarcoma (SS) varies from 3.2 to 4.65 cases per million populations in the USA.

 

The competitive landscape of Synovial Sarcoma includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Synovial Sarcoma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Synovial Sarcoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Synovial Sarcoma – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          CFT8634          C4 Therapeutics Inc      Phase 2

2          Ramucirumab   Eli Lilly and Company    Phase 2

3          FHD-609           Foghorn Therapeutics Inc.         Phase 1

4          OTSA101-DTPA-111In  OncoTherapy Science, Inc.        Phase 1

5          ADP-A2M4        Adaptimmune    Phase 2

6          AL3818 Advenchen Laboratories, LLC    Phase 3

7          Tazemetostat    Epizyme, Inc.    Phase 2

8          Itacitinib            Incyte Corporation         Phase 1

9          CAB-AXL-ADC  BioAtla, Inc.      Phase 2

10        CAR-T cell immunotherapy        Shenzhen BinDeBio Ltd.            Phase 2

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033